{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+receptor+radionuclide+therapy+%28PRRT%29",
    "query": {
      "intervention": "Peptide receptor radionuclide therapy (PRRT)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 22,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peptide+receptor+radionuclide+therapy+%28PRRT%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T05:52:50.366Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03049189",
      "title": "Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "177Lu-edotreotide PRRT",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Amino-Acid Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ITM Solucin GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2017-02-02",
      "completion_date": "2029-11",
      "has_results": true,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-06T05:52:50.366Z",
      "location_count": 6,
      "location_summary": "Gilbert, Arizona • Stanford, California • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03049189"
    },
    {
      "nct_id": "NCT06016855",
      "title": "Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Digestive System Neuroendocrine Tumor G1",
        "Digestive System Neuroendocrine Tumor G2",
        "Metastatic Digestive System Neuroendocrine Neoplasm",
        "Metastatic Malignant Neoplasm in the Liver",
        "Pancreatic Neuroendocrine Tumor G1",
        "Pancreatic Neuroendocrine Tumor G2"
      ],
      "interventions": [
        {
          "name": "Tumor Debulking",
          "type": "PROCEDURE"
        },
        {
          "name": "Lutetium Lu 177 Dotatate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Copper Cu 64 Dotatate",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2024-05-31",
      "completion_date": "2028-05-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-10-06T05:52:50.366Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06016855"
    },
    {
      "nct_id": "NCT03197012",
      "title": "Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "90Y-DOTA-TOC",
          "type": "DRUG"
        },
        {
          "name": "68Ga-DOTA-TOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Hope",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2017-07-01",
      "completion_date": "2019-05-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-10-06T05:52:50.366Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03197012"
    },
    {
      "nct_id": "NCT05249114",
      "title": "Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Lu-177",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-12-28",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-06T05:52:50.366Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05249114"
    },
    {
      "nct_id": "NCT03923257",
      "title": "Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Pheochromocytoma",
        "Paraganglioma"
      ],
      "interventions": [
        {
          "name": "177Lu-DOTA-tyr3-OCTREOTATE",
          "type": "DRUG"
        },
        {
          "name": "Peptide Receptor Radiotherapy (PRRT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Sue O'Dorisio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "1 Year to 20 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-08-04",
      "completion_date": "2021-06-03",
      "has_results": false,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-10-06T05:52:50.366Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03923257"
    },
    {
      "nct_id": "NCT04919226",
      "title": "Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT",
          "type": "DRUG"
        },
        {
          "name": "CAPTEM (Capecitabine and Temozolomide)",
          "type": "DRUG"
        },
        {
          "name": "Amino-Acid Solution",
          "type": "OTHER"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ITM Solucin GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 259,
      "start_date": "2021-12-21",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-10-06T05:52:50.366Z",
      "location_count": 14,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04919226"
    },
    {
      "nct_id": "NCT03044977",
      "title": "Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumor, Malignant",
        "Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting"
      ],
      "interventions": [
        {
          "name": "90Y-DOTA-3-Tyr-Octreotide",
          "type": "DRUG"
        },
        {
          "name": "131I-MIBG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Bushnell",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2017-05-07",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2023-08-16",
      "last_synced_at": "2026-10-06T05:52:50.366Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03044977"
    },
    {
      "nct_id": "NCT04090034",
      "title": "Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuroendocrine Tumors",
        "Gastroenteropancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Peptide Receptor Radionuclide Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Methodist Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-03-28",
      "completion_date": "2026-06-28",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-10-06T05:52:50.366Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04090034"
    },
    {
      "nct_id": "NCT04711135",
      "title": "Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastroenteropancreatic Neuroendocrine Tumors",
        "Pheochromocytoma",
        "Paraganglioma"
      ],
      "interventions": [
        {
          "name": "Lutetium [177Lu] oxodotreotide/dotatate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advanced Accelerator Applications",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 11,
      "start_date": "2022-08-31",
      "completion_date": "2034-02-06",
      "has_results": true,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-06T05:52:50.366Z",
      "location_count": 3,
      "location_summary": "Lexington, Kentucky • Cincinnati, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04711135"
    },
    {
      "nct_id": "NCT06500065",
      "title": "68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Gallium Ga 68-HA-DOTA-TATE",
          "type": "RADIATION"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-09-30",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-10-06T05:52:50.366Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06500065"
    }
  ]
}